Glaukos Gains FDA Nod for iDose TR Re-Administration
Event summary
- Glaukos received FDA approval for an NDA labeling supplement allowing for re-administration of its iDose TR device.
- The approval is based on accumulated clinical evidence demonstrating the safety and tolerability of repeat iDose TR use.
- Physicians can now re-administer iDose TR more than once in patients with healthy corneas, as defined by endothelial cell density parameters.
- Clinical trials showed no clinically significant corneal endothelial cell loss through three years and a favorable safety profile with a second administration.
The big picture
This FDA approval expands the potential patient pool for iDose TR and provides physicians with greater flexibility in managing glaucoma treatment. The re-administration allowance addresses a key limitation of the initial approval and could significantly boost the device’s lifetime value. Glaukos’ success in demonstrating long-term corneal safety is a testament to its product development capabilities and reinforces its position in the growing market for minimally invasive glaucoma surgery (MIGS).
What we're watching
- Adoption Rate
- The pace at which physicians incorporate repeat iDose TR administrations into their treatment protocols will determine the full revenue impact of this approval.
- Corneal Health
- Continued monitoring of patient corneal health following repeat iDose TR administrations will be critical to maintaining the device’s safety profile and avoiding future regulatory scrutiny.
- Competitive Response
- Competitors in the glaucoma treatment space may accelerate development of alternative long-duration therapies in response to Glaukos’ expanded iDose TR utility.
Related topics